Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine

被引:987
作者
Weerink, Maud A. S. [1 ]
Struys, Michel M. R. F. [1 ,2 ]
Hannivoort, Laura N. [1 ]
Barends, Clemens R. M. [1 ]
Absalom, Anthony R. [1 ]
Colin, Pieter [1 ,3 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, POB 30001, NL-9700 RB Groningen, Netherlands
[2] Univ Ghent, Dept Anesthesia & Perioperat Med, Ghent, Belgium
[3] Univ Ghent, Fac Pharmaceut Sci, Dept Bioanal, Ghent, Belgium
关键词
MINIMUM ALVEOLAR CONCENTRATION; INCREASING PLASMA-CONCENTRATIONS; ISCHEMIA-REPERFUSION INJURY; BRACHIAL-PLEXUS BLOCK; INTRANASAL DEXMEDETOMIDINE; INTRAVENOUS DEXMEDETOMIDINE; DOUBLE-BLIND; INTRAMUSCULAR DEXMEDETOMIDINE; POPULATION PHARMACOKINETICS; INTENSIVE-CARE;
D O I
10.1007/s40262-017-0507-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dexmedetomidine is an alpha(2)-adrenoceptor agonist with sedative, anxiolytic, sympatholytic, and analgesic-sparing effects, and minimal depression of respiratory function. It is potent and highly selective for alpha(2)-receptors with an alpha(2):alpha(1) ratio of 1620:1. Hemodynamic effects, which include transient hypertension, bradycardia, and hypotension, result from the drug's peripheral vasoconstrictive and sympatholytic properties. Dexmedetomidine exerts its hypnotic action through activation of central pre- and postsynaptic alpha(2)-receptors in the locus coeruleus, thereby inducting a state of unconsciousness similar to natural sleep, with the unique aspect that patients remain easily rousable and cooperative. Dexmedetomidine is rapidly distributed and is mainly hepatically metabolized into inactive metabolites by glucuronidation and hydroxylation. A high inter-individual variability in dexmedetomidine pharmacokinetics has been described, especially in the intensive care unit population. In recent years, multiple pharmacokinetic non-compartmental analyses as well as population pharmacokinetic studies have been performed. Body size, hepatic impairment, and presumably plasma albumin and cardiac output have a significant impact on dexmedetomidine pharmacokinetics. Results regarding other covariates remain inconclusive and warrant further research. Although initially approved for intravenous use for up to 24 h in the adult intensive care unit population only, applications of dexmedetomidine in clinical practice have been widened over the past few years. Procedural sedation with dexmedetomidine was additionally approved by the US Food and Drug Administration in 2003 and dexmedetomidine has appeared useful in multiple off-label applications such as pediatric sedation, intranasal or buccal administration, and use as an adjuvant to local analgesia techniques.
引用
收藏
页码:893 / 913
页数:21
相关论文
共 146 条
[1]   A COMPARISON OF DEXMEDETOMIDINE, AN ALPHA2-ADRENOCEPTOR AGONIST, AND MIDAZOLAM AS IM PREMEDICATION FOR MINOR GYNECOLOGICAL SURGERY [J].
AANTAA, R ;
JAAKOLA, ML ;
KALLIO, A ;
KANTO, J ;
SCHEININ, M ;
VUORINEN, J .
BRITISH JOURNAL OF ANAESTHESIA, 1991, 67 (04) :402-409
[2]   Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine [J].
Aantaa, R ;
Jaakola, ML ;
Kallio, A ;
Kanto, J .
ANESTHESIOLOGY, 1997, 86 (05) :1055-1060
[3]   INTRAMUSCULAR DEXMEDETOMIDINE, A NOVEL ALPHA2-ADRENOCEPTOR AGONIST, AS PREMEDICATION FOR MINOR GYNECOLOGICAL SURGERY [J].
AANTAA, R ;
KANTO, J ;
SCHEININ, M .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1991, 35 (04) :283-288
[4]  
Abbott Laboratories, 2001, PREC APPR DOC
[5]   IV and Perineural Dexmedetomidine Similarly Prolong the Duration of Analgesia after Interscalene Brachial Plexus Block A Randomized, Three-arm, Triple-masked, Placebo-controlled Trial [J].
Abdallah, Faraj W. ;
Dwyer, Tim ;
Chan, Vincent W. S. ;
Niazi, Ahtsham U. ;
Ogilvie-Harris, Darrell J. ;
Oldfield, Stephanie ;
Patel, Rajesh ;
Oh, Justin ;
Brull, Richard .
ANESTHESIOLOGY, 2016, 124 (03) :683-695
[6]   The Facilitatory Effects of Intravenous Dexmedetomidine on the Duration of Spinal Anesthesia: A Systematic Review and Meta-Analysis [J].
Abdallah, Faraj W. ;
Abrishami, Amir ;
Brull, Richard .
ANESTHESIA AND ANALGESIA, 2013, 117 (01) :271-278
[7]   THE EFFECT OF INTRAVENOUSLY ADMINISTERED DEXMEDETOMIDINE ON PERIOPERATIVE HEMODYNAMICS AND ISOFLURANE REQUIREMENTS IN PATIENTS UNDERGOING ABDOMINAL HYSTERECTOMY [J].
AHO, M ;
LEHTINEN, AM ;
ERKOLA, O ;
KALLIO, A ;
KORTTILA, K .
ANESTHESIOLOGY, 1991, 74 (06) :997-1002
[8]   Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans [J].
Angst, MS ;
Ramaswamy, B ;
Davies, MF ;
Maze, M .
ANESTHESIOLOGY, 2004, 101 (03) :744-752
[9]   Bioavailability of dexmedetomidine after extravascular doses in healthy subjects [J].
Anttila, M ;
Penttilä, J ;
Helminen, A ;
Vuorilehto, L ;
Scheinin, H .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :691-693
[10]  
Bakhamees Hassan S., 2007, Middle East Journal of Anesthesiology, V19, P537